ezetimibe has been researched along with Metabolic Syndrome in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 25 (58.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bujas-Bobanovic, M; Ginsberg, HN; Henry, RR; Letierce, A; Louie, MJ; Müller-Wieland, D; Taub, PR | 1 |
| Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Abate, N; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M; Sallam, HS | 1 |
| Federici, M | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Ahn, Y; Chae, IH; Han, KR; Hong, SJ; Hong, TJ; Jeon, DW; Jeon, HK; Kim, HS; Kim, KJ; Kim, SH; Kim, W; Kwak, CH; Lee, N; Moon, KW; Nam, CW; Park, S; Park, TH; Rha, SW; Rhee, MY; Yoon, YW | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Catapano, AL; Farnier, M; Foody, J; Hanson, ME; Jensen, E; Musliner, TA; Polis, AB; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Dallinga-Thie, GM; Hajer, GR; van Vark-van der Zee, LC; Visseren, FL | 1 |
| Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I | 1 |
| Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van der Graaf, Y; Visseren, FL | 1 |
| de Bree, P; Doevendans, PA; Hajer, GR; Hoefer, IE; Olijhoek, JK; Rafii, S; Verhaar, MC; Visseren, FL; Westerweel, PE | 1 |
| Hughes, S | 1 |
| Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Visseren, FL; Westerink, J | 1 |
| Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A | 1 |
| Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Ishikawa, K; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y | 1 |
| Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S | 1 |
| Braga, MF; Gupta, M; Herjikaka, S; Kajil, M; Quan, A; Szmitko, PE; Teoh, H; Tsigoulis, M; Verma, S | 1 |
| Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Matsuyama, A; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M | 1 |
| Yoshida, M | 1 |
| Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Kotani, K; Sakane, N; Taniguchi, N | 1 |
| Adeli, K; Baker, C; Hussain, MM; Iqbal, J; Lino, M; Naples, M | 1 |
| Dohi, Y; Goto, Y; Hashimoto, T; Kimura, G; Okado, T; Takase, H | 1 |
| Hu, YW; Wang, Q; Yang, JY; Zhang, P; Zheng, L | 1 |
| Borthwick, F; Cheeseman, CI; Hassanali, Z; Mangat, R; Proctor, SD; Russell, JC; Uwiera, RR; Vine, DF; Warnakula, S | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Gumbiner, B; Lee, M; Maccubbin, D; Masana, L; Shah, A; Simons, L; Tonkon, M | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 1 |
| Ducobu, J | 1 |
| Brady, WE; Denke, M; Gazzara, RA; McBride, P; Pearson, T; Tershakovec, AM | 1 |
| Devaraj, S; Jialal, I | 1 |
| Bissonnette, S; Boukas, S; Habib, R; Sampalis, JS | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
| Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van Vark-van der Zee, LC; Visseren, FL | 1 |
7 review(s) available for ezetimibe and Metabolic Syndrome
| Article | Year |
|---|---|
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Incretins; Insulin; Insulin Resistance; Lipids; Lipoproteins; Metabolic Syndrome; Metformin; Niacin; Thiazolidinediones | 2014 |
Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lipoproteins; Liver; Metabolic Syndrome; Treatment Outcome | 2015 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biological Transport; Cholesterol; Chylomicrons; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Intestines; Metabolic Syndrome; Rats | 2010 |
Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Fatty Liver; Humans; Liver; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease | 2011 |
[Progress of Niemann-Pick type C1 Like 1 on cholesterol metabolism].
Topics: Azetidines; Biological Transport; Cholesterol; Ezetimibe; Fatty Acids; Humans; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 2 | 2012 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
18 trial(s) available for ezetimibe and Metabolic Syndrome
| Article | Year |
|---|---|
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Republic of Korea; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Triglycerides | 2016 |
The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Topics: Adolescent; Adult; Aged; Azetidines; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2009 |
The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prospective Studies; Simvastatin; Triglycerides | 2008 |
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cross-Over Studies; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Ezetimibe; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin; Stem Cells | 2008 |
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter,
Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2009 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2010 |
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Triglycerides | 2011 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Research Design; Simvastatin; Treatment Outcome | 2011 |
Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Humans; Hypercholesterolemia; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Tomography, X-Ray Computed | 2012 |
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged | 2004 |
Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Placebos | 2006 |
Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Metabolic Syndrome; Middle Aged; Risk | 2007 |
Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Combinations; Ezetimibe; Fasting; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2008 |
18 other study(ies) available for ezetimibe and Metabolic Syndrome
| Article | Year |
|---|---|
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Metabolic Syndrome; Middle Aged; PCSK9 Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides | 2019 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Male; Metabolic Syndrome; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2016 |
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Triglycerides | 2008 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Deoxyguanosine; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitrates; Nitrites; Oxidative Stress; Tumor Necrosis Factor-alpha | 2010 |
Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
Topics: Adipokines; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Vascular Diseases | 2010 |
Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Base Sequence; CD36 Antigens; Chylomicrons; Disease Models, Animal; DNA Primers; Ezetimibe; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Hypertriglyceridemia; Intestinal Absorption; Lipoproteins, VLDL; Lymph; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Postprandial Period; RNA, Messenger; Triglycerides; Triolein | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Female; Humans; Lipids; Lipoproteins; Male; Metabolic Syndrome; Triglycerides | 2012 |
Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Chylomicrons; Cricetinae; Diet, High-Fat; Disease Models, Animal; Ezetimibe; Glucose Tolerance Test; Male; Mesocricetus; Metabolic Syndrome; Treatment Outcome | 2012 |
Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biglycan; Cholesterol; Ezetimibe; Insulin Resistance; Lipoproteins; Male; Metabolic Syndrome; Rats; Simvastatin | 2012 |
Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
Topics: Acetylcholine; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant | 2005 |
Therapy and clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Metabolic Syndrome; Models, Biological; Obesity; Risk Factors | 2007 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |